Mr. Greg Cavers reports
HELUS PHARMA TO PRESENT TOPLINE RESULTS FROM PHASE 3 APPROACH STUDY EVALUATING HLP003 AS ADJUNCTIVE TREATMENT IN MAJOR DEPRESSIVE DISORDER ON NOVEMBER 16, 2026
Helus Pharma Inc. will host a webcast at 8 a.m. EDT to present top-line results from its phase 3 Approach study evaluating HLP003 in major depressive disorder.
Please visit the events and presentations page of Helus Pharma's website. The archived webcast will be available on the company's website on the events and presentations page following the presentation.
About Helus Pharma
Inc.
Helus Pharma is a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.
Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the adjunctive treatment of MDD that has received breakthrough therapy designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.
The company operates in Canada, the United States, the United Kingdom and Ireland.
We seek Safe Harbor.
© 2026 Canjex Publishing Ltd. All rights reserved.